Please assess the completion status of the following clinical trial:

Trial Title: Isovue in Peripheral Digital Subtraction Angiography (DSA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* provides written informed consent;~* at least 18 years of age;~* scheduled to undergo peripheral DSA for the diagnosis and/or treatment of PAOD~Exclusion Criteria:~* pregnant or lactating female;~* known allergies to one more more ingredients in wither product;~* history of severe congestive heart failure (Class IV);~* previously enrolled or received an investigational compound within 30 days;~* history of hypersensitivity to iodinated contrast agents;~* renal impairment eGFR \<60 mL/min/1.73m2, calculated using the MDRD study equation~* any other medical condition decreasing chances of obtaining reliable data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isovue 250 (iopamidol) (Type: EXPERIMENTAL): None
- Visipaque 270 (iodixanol) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).